{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:24:53Z","timestamp":1788351893872,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01722-1","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:11:30Z","timestamp":1788351090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Esketamine Use and Attempted Suicide or Intentional Self-Harm Among Individuals with Treatment-Resistant Depression: A Retrospective Cohort Study"],"prefix":"10.1007","author":[{"given":"You","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra S.","family":"Storaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1724-6897","authenticated-orcid":false,"given":"Jason B.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1722_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adher. 2012;6:369\u201388. https:\/\/doi.org\/10.2147\/PPA.S29716.","journal-title":"Patient Prefer Adher"},{"key":"1722_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","volume":"80","author":"J Lundberg","year":"2023","unstructured":"Lundberg J, Cars T, L\u00f6\u00f6v S\u00c5, S\u00f6derling J, Sundstr\u00f6m J, Tiihonen J, et al. Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiat. 2023;80:167\u201375. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3860.","journal-title":"JAMA Psychiat"},{"key":"1722_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22:394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120.","journal-title":"World Psychiatry"},{"key":"1722_CR4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699","volume":"82","author":"M Zhdanava","year":"2021","unstructured":"Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82:20m13699. https:\/\/doi.org\/10.4088\/JCP.20m13699.","journal-title":"J Clin Psychiatry"},{"key":"1722_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100426","volume":"22","author":"VK Chan","year":"2022","unstructured":"Chan VK, Cheung EC, Chan SS, Knapp M, Hayes JF, Fan M, et al. Mortality-causing mechanisms and healthcare resource utilisation of treatment-resistant depression: a six-year population-based cohort study. Lancet Reg Health West Pac. 2022;22:100426. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100426.","journal-title":"Lancet Reg Health West Pac."},{"key":"1722_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4088\/JCP.v63n1102","volume":"63","author":"WH Crown","year":"2002","unstructured":"Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963\u201371. https:\/\/doi.org\/10.4088\/JCP.v63n1102.","journal-title":"J Clin Psychiatry"},{"key":"1722_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105594","volume":"159","author":"D Arnone","year":"2024","unstructured":"Arnone D, Karmegam SR, \u00d6stlundh L, Alkhyeli F, Alhammadi L, Alhammadi S, et al. Risk of suicidal behavior in patients with major depression and bipolar disorder\u2014a systematic review and meta-analysis of registry-based studies. Neurosci Biobehav Rev. 2024;159:105594. https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105594.","journal-title":"Neurosci Biobehav Rev"},{"key":"1722_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2018.04.016","volume":"235","author":"IO Bergfeld","year":"2018","unstructured":"Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362\u20137. https:\/\/doi.org\/10.1016\/j.jad.2018.04.016.","journal-title":"J Affect Disord"},{"key":"1722_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000442293","volume":"85","author":"C Braun","year":"2016","unstructured":"Braun C, Bschor T, Franklin J, Baethge C. Suicides and suicide attempts during long-term treatment with antidepressants: a meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom. 2016;85:171\u20139. https:\/\/doi.org\/10.1159\/000442293.","journal-title":"Psychother Psychosom"},{"key":"1722_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1371139","volume":"15","author":"SC Civardi","year":"2024","unstructured":"Civardi SC, Besana F, Carnevale Miacca G, Mazzoni F, Arienti V, Politi P, et al. Risk factors for suicidal attempts in a sample of outpatients with treatment-resistant depression: an observational study. Front Psychiatry. 2024;15:1371139. https:\/\/doi.org\/10.3389\/fpsyt.2024.1371139.","journal-title":"Front Psychiatry"},{"key":"1722_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3171","volume":"13","author":"DM Kern","year":"2023","unstructured":"Kern DM, Canuso CM, Daly E, Johnson JC, Fu DJ, Doherty T, et al. Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone. Brain Behav. 2023;13:e3171. https:\/\/doi.org\/10.1002\/brb3.3171.","journal-title":"Brain Behav"},{"key":"1722_CR12","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/jamapsychiatry.2023.2833","volume":"80","author":"J Lundberg","year":"2023","unstructured":"Lundberg J, Cars T, Lampa E, Ekholm Selling K, Leval A, Gannedahl A, et al. Determinants and outcomes of suicidal behavior among patients with major depressive disorder. JAMA Psychiat. 2023;80:1218\u201325. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.2833.","journal-title":"JAMA Psychiat"},{"key":"1722_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/13811118.2019.1691692","volume":"25","author":"J Reutfors","year":"2021","unstructured":"Reutfors J, Andersson TM, Tanskanen A, DiBernardo A, Li G, Brandt L, et al. Risk factors for suicide and suicide attempts among patients with treatment-resistant depression: nested case-control study. Arch Suicide Res. 2021;25:424\u201338. https:\/\/doi.org\/10.1080\/13811118.2019.1691692.","journal-title":"Arch Suicide Res"},{"key":"1722_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.11250","volume":"6","author":"JL Havlik","year":"2023","unstructured":"Havlik JL, Murphy MJ, Gong N, Tang D, Krystal JH. Characteristics of esketamine prescribers among Medicare beneficiaries in the United States, 2019\u20132020. JAMA Netw Open. 2023;6:e2311250. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.11250.","journal-title":"JAMA Netw Open"},{"key":"1722_CR15","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/biomedicines12102283","volume":"12","author":"P Kawczak","year":"2024","unstructured":"Kawczak P, Feszak I, B\u0105czek T. Ketamine, esketamine, and arketamine: their mechanisms of action and applications in the treatment of depression and alleviation of depressive symptoms. Biomedicines. 2024;12:2283. https:\/\/doi.org\/10.3390\/biomedicines12102283.","journal-title":"Biomedicines"},{"key":"1722_CR16","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11810","volume":"25","author":"O Vasiliu","year":"2023","unstructured":"Vasiliu O. Esketamine for treatment-resistant depression: a review of clinical evidence (review). Exp Ther Med. 2023;25:111. https:\/\/doi.org\/10.3892\/etm.2023.11810.","journal-title":"Exp Ther Med"},{"key":"1722_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cpt.3478","volume":"117","author":"KA Vekhova","year":"2025","unstructured":"Vekhova KA, Namiot ED, Jonsson J, Schi\u00f6th HB. Ketamine and esketamine in clinical trials: FDA-approved and emerging indications, trial trends with putative mechanistic explanations. Clin Pharmacol Ther. 2025;117:374\u201386. https:\/\/doi.org\/10.1002\/cpt.3478.","journal-title":"Clin Pharmacol Ther"},{"key":"1722_CR18","unstructured":"U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information. Revised January 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211243s019lbl.pdf."},{"key":"1722_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","volume":"41","author":"CM Canuso","year":"2021","unstructured":"Canuso CM, Ionescu DF, Li X, Qiu X, Lane R, Turkoz I, et al. Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior. J Clin Psychopharmacol. 2021;41:516\u201324. https:\/\/doi.org\/10.1097\/JCP.0000000000001465.","journal-title":"J Clin Psychopharmacol"},{"key":"1722_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620\u201330. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17060720.","journal-title":"Am J Psychiatry"},{"key":"1722_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","volume":"24","author":"DF Ionescu","year":"2021","unstructured":"Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24:22\u201331. https:\/\/doi.org\/10.1093\/ijnp\/pyaa068.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1722_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-021-00851-8","volume":"35","author":"S Nikayin","year":"2021","unstructured":"Nikayin S, Sanacora G. Evaluating the role of ketamine\/esketamine in the management of major depressive disorder with suicide risk. CNS Drugs. 2021;35:1069\u201379. https:\/\/doi.org\/10.1007\/s40263-021-00851-8.","journal-title":"CNS Drugs"},{"key":"1722_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.psycr.2023.100104","volume":"2","author":"WF Rayburn","year":"2023","unstructured":"Rayburn WF, Albright BB. Completed suicides and intranasal esketamine therapy: a case report and case series. Psychiatry Res Case Rep. 2023;2:100104. https:\/\/doi.org\/10.1016\/j.psycr.2023.100104.","journal-title":"Psychiatry Res Case Rep"},{"key":"1722_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40290-023-00467-x","volume":"37","author":"Z Yao","year":"2023","unstructured":"Yao Z, McCall WV. Designing clinical trials to assess the impact of pharmacological treatment for suicidal ideation\/behavior: issues and potential solutions. Pharm Med. 2023;37:221\u201332. https:\/\/doi.org\/10.1007\/s40290-023-00467-x.","journal-title":"Pharm Med"},{"key":"1722_CR25","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/cer-2022-0149","volume":"11","author":"M Brendle","year":"2022","unstructured":"Brendle M, Ahuja S, Valle MD, Moore C, Thielking P, Malone DC, et al. Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study. J Comp Eff Res. 2022;11:1323\u201336. https:\/\/doi.org\/10.2217\/cer-2022-0149.","journal-title":"J Comp Eff Res."},{"key":"1722_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpsychires.2024.04.008","volume":"174","author":"L Dvorak","year":"2024","unstructured":"Dvorak L, Bloemhof-Bris E, Shelef A, Halperin D, Wexler G, Talmon O, et al. Efficacy of esketamine among patients with treatment resistant depression in a \u2018real world\u2019 health-care setting in Israel. J Psychiatr Res. 2024;174:66\u201372. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.04.008.","journal-title":"J Psychiatr Res"},{"key":"1722_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2024.100809","volume":"17","author":"T Gil","year":"2024","unstructured":"Gil T, Bonetti TCS. Efficacy of intravenous esketamine in reducing suicidal ideation and major depressive symptoms: a real-world evidence study. J Affect Disord Rep. 2024;17:100809. https:\/\/doi.org\/10.1016\/j.jadr.2024.100809.","journal-title":"J Affect Disord Rep."},{"key":"1722_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116125","volume":"340","author":"G Gutierrez","year":"2024","unstructured":"Gutierrez G, Swainson J, Ravindran N, Lam RW, Giacobbe P, Karthikeyan G, et al. IN esketamine and IV ketamine: results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression. Psychiatry Res. 2024;340:116125. https:\/\/doi.org\/10.1016\/j.psychres.2024.116125.","journal-title":"Psychiatry Res"},{"key":"1722_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","volume":"319","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell\u2019Osso B, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). J Affect Disord. 2022;319:646\u201354. https:\/\/doi.org\/10.1016\/j.jad.2022.09.043.","journal-title":"J Affect Disord"},{"key":"1722_CR30","doi-asserted-by":"publisher","first-page":"22m14548","DOI":"10.4088\/JCP.22m14548","volume":"84","author":"B Singh","year":"2023","unstructured":"Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, et al. Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study. J Clin Psychiatry. 2023;84:22m14548. https:\/\/doi.org\/10.4088\/JCP.22m14548.","journal-title":"J Clin Psychiatry"},{"key":"1722_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","volume":"21","author":"S Nikayin","year":"2022","unstructured":"Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin Drug Saf. 2022;21:777\u201387. https:\/\/doi.org\/10.1080\/14740338.2022.2066651.","journal-title":"Expert Opin Drug Saf"},{"key":"1722_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2026.104983","volume":"120","author":"F Raffone","year":"2026","unstructured":"Raffone F, Mazzoni F, De Ciechi A, Girone N, Macellaro M, Martinotti G, et al. Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: a real-world longitudinal study of suicidal ideation and self-harm. Asian J Psychiatry. 2026;120:104983. https:\/\/doi.org\/10.1016\/j.ajp.2026.104983.","journal-title":"Asian J Psychiatry"},{"key":"1722_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1176\/appi.ajp-rj.2023.180305","volume":"18","author":"F Bell","year":"2023","unstructured":"Bell F. Acute suicidal ideation in the context of esketamine maintenance therapy. Am J Psychiatry Resid J. 2023;18:15\u20137. https:\/\/doi.org\/10.1176\/appi.ajp-rj.2023.180305.","journal-title":"Am J Psychiatry Resid J."},{"key":"1722_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom. 2021;90:41\u20138. https:\/\/doi.org\/10.1159\/000510703.","journal-title":"Psychother Psychosom"},{"key":"1722_CR35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/14740338.2024.2368827","volume":"24","author":"RS McIntyre","year":"2025","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Teopiz KM, Kwan ATH. The association between ketamine and esketamine and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2025;24:909\u201314. https:\/\/doi.org\/10.1080\/14740338.2024.2368827.","journal-title":"Expert Opin Drug Saf"},{"key":"1722_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.849758","volume":"13","author":"H Guo","year":"2022","unstructured":"Guo H, Wang B, Yuan S, Wu S, Liu J, He M, et al. Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Front Pharmacol. 2022;13:849758. https:\/\/doi.org\/10.3389\/fphar.2022.849758.","journal-title":"Front Pharmacol"},{"key":"1722_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.9758\/cpn.2021.19.2.341","volume":"19","author":"SM Wang","year":"2021","unstructured":"Wang SM, Kim NY, Na HR, Lim HK, Woo YS, Pae CU, et al. Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis. Clin Psychopharmacol Neurosci. 2021;19:341\u201354. https:\/\/doi.org\/10.9758\/cpn.2021.19.2.341.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1722_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00325","volume":"11","author":"M Pompili","year":"2020","unstructured":"Pompili M. Intranasal esketamine and current suicidal ideation with intent in major depression disorder: beat the clock, save a life, start a strategy. Front Psychiatry. 2020;11:325. https:\/\/doi.org\/10.3389\/fpsyt.2020.00325.","journal-title":"Front Psychiatry"},{"key":"1722_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2024.100104","volume":"11","author":"MZ Price","year":"2024","unstructured":"Price MZ, Price RL. Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression. Biomark Neuropsychiatry. 2024;11:100104. https:\/\/doi.org\/10.1016\/j.bionps.2024.100104.","journal-title":"Biomark Neuropsychiatry."},{"key":"1722_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1176\/appi.ajp.20241177","volume":"182","author":"SJ Mathew","year":"2025","unstructured":"Mathew SJ, Murphy N. Six years after approval of esketamine nasal spray for serious depression: clinical conundrums and unanswered questions. Am J Psychiatry. 2025;182:227\u201330. https:\/\/doi.org\/10.1176\/appi.ajp.20241177.","journal-title":"Am J Psychiatry"},{"key":"1722_CR41","unstructured":"Kythera Labs. Wayfinder data sourcing. https:\/\/www.kytheralabs.com\/wayfinder-platform\/wayfinder-data-sourcing-kythera-labs. Accessed 29 July 2026."},{"issue":"2","key":"1722_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.36469\/001c.87538","volume":"10","author":"O Baser","year":"2023","unstructured":"Baser O, Samayoa G, Yapar N, Baser E, Mete F. Use of open claims vs closed claims in health outcomes research. J Health Econ Outcomes Res. 2023;10(2):44\u201352. https:\/\/doi.org\/10.36469\/001c.87538.","journal-title":"J Health Econ Outcomes Res."},{"issue":"6","key":"1722_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxad074","volume":"1","author":"JB Gibbons","year":"2023","unstructured":"Gibbons JB, Cram P, Meiselbach MK, Anderson GF, Bai G. Comparison of social determinants of health in Medicaid vs commercial health plans. Health Aff (Millwood). 2023;1(6):qxad074. https:\/\/doi.org\/10.1093\/haschl\/qxad074.","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"1722_CR44","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s11606-024-09040-x","volume":"40","author":"JB Gibbons","year":"2025","unstructured":"Gibbons JB, Plummer E, Magrath WJ, Bai G. Insurance type and social determinants of health for individuals seeking gender-affirming care in the United States. J Gen Intern Med. 2025;40(6):1462\u20136. https:\/\/doi.org\/10.1007\/s11606-024-09040-x.","journal-title":"J Gen Intern Med"},{"key":"1722_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-024-06882-5","volume":"24","author":"O Baser","year":"2024","unstructured":"Baser O, Isenman L, Baser E, Li W, Cigdem B. Neighborhood socioeconomic status and postpartum depression among commercial health insurance enrollees: a retrospective cohort study. BMC Pregnancy Childb. 2024;24:732. https:\/\/doi.org\/10.1186\/s12884-024-06882-5.","journal-title":"BMC Pregnancy Childb"},{"key":"1722_CR46","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150\u201361. https:\/\/doi.org\/10.1002\/pst.433.","journal-title":"Pharm Stat"},{"key":"1722_CR47","unstructured":"Hedegaard H, Schoenbaum M, Claassen C, Crosby A, Holland K, Proescholdbell S. Issues in developing a surveillance case definition for nonfatal suicide attempt and intentional self-harm using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) coded data. Natl Health Stat Rep. 2018;(108):1\u201319. https:\/\/www.cdc.gov\/nchs\/data\/nhsr\/nhsr108.pdf."},{"key":"1722_CR48","doi-asserted-by":"publisher","DOI":"10.1201\/b18698","volume-title":"Statistical methods for drug safety","author":"RD Gibbons","year":"2015","unstructured":"Gibbons RD, Amatya AK. Statistical methods for drug safety. Boca Raton: CRC Press; 2015. https:\/\/doi.org\/10.1201\/b18698."},{"key":"1722_CR49","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661\u201379. https:\/\/doi.org\/10.1002\/sim.6607.","journal-title":"Stat Med"},{"key":"1722_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15:14\u201320. https:\/\/doi.org\/10.1093\/ckj\/sfab158.","journal-title":"Clin Kidney J"},{"key":"1722_CR51","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hern\u00e1n MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656\u201364. https:\/\/doi.org\/10.1093\/aje\/kwn164.","journal-title":"Am J Epidemiol"},{"key":"1722_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2167696815621645","volume":"4","author":"F Thoemmes","year":"2016","unstructured":"Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. Emerg Adulthood. 2016;4:40\u201359. https:\/\/doi.org\/10.1177\/2167696815621645.","journal-title":"Emerg Adulthood"},{"key":"1722_CR53","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1002\/sim.10188","volume":"43","author":"D Adenyo","year":"2024","unstructured":"Adenyo D, Guertin JR, Candas B, Sirois C, Talbot D. Evaluation and comparison of covariate balance metrics in studies with time-dependent confounding. Stat Med. 2024;43:4437\u201355. https:\/\/doi.org\/10.1002\/sim.10188.","journal-title":"Stat Med"},{"key":"1722_CR54","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53987","volume":"16","author":"S Kumari","year":"2024","unstructured":"Kumari S, Chaudhry HA, Sagot A, Doumas S, Abdullah H, Alcera E, et al. Exploring esketamine\u2019s therapeutic outcomes as an FDA-designated breakthrough for treatment-resistant depression and major depressive disorder with suicidal intent: a narrative review. Cureus. 2024;16:e53987. https:\/\/doi.org\/10.7759\/cureus.53987.","journal-title":"Cureus"},{"key":"1722_CR55","doi-asserted-by":"publisher","first-page":"70","DOI":"10.9758\/cpn.2022.20.1.70","volume":"20","author":"HJ Jeon","year":"2022","unstructured":"Jeon HJ, Ju PC, Sulaiman AH, Aziz SA, Paik JW, Tan W, et al. Long-term safety and efficacy of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression\u2014an Asian sub-group analysis from the SUSTAIN-2 study. Clin Psychopharmacol Neurosci. 2022;20:70\u201386. https:\/\/doi.org\/10.9758\/cpn.2022.20.1.70.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1722_CR56","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","volume":"48","author":"N Zaki","year":"2023","unstructured":"Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023;48:1225\u201333. https:\/\/doi.org\/10.1038\/s41386-023-01577-5.","journal-title":"Neuropsychopharmacology"},{"key":"1722_CR57","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jamapsychiatry.2013.2105","volume":"70","author":"AS Iltis","year":"2013","unstructured":"Iltis AS, Misra S, Dunn LB, Brown GK, Campbell A, Earll SA, et al. Addressing risks to advance mental health research. JAMA Psychiat. 2013;70:1363\u201371. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.2105.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"1722_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15041629","volume":"15","author":"V Martiadis","year":"2026","unstructured":"Martiadis V, Raffone F, Testa S, Iaccarino C, Giunnelli P, Orrico A, et al. Integrating psychiatric, psychotherapeutic, and nursing care in intranasal esketamine for treatment-resistant depression. J Clin Med. 2026;15(4):1629. https:\/\/doi.org\/10.3390\/jcm15041629.","journal-title":"J Clin Med"},{"key":"1722_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5734","volume":"33","author":"GE Simon","year":"2024","unstructured":"Simon GE, Shortreed SM, Johnson E, Yaseen ZS, Stone M, Mosholder AD, et al. Predicting risk of suicidal behavior from insurance claims data vs linked data from insurance claims and electronic health records. Pharmacoepidemiol Drug Saf. 2024;33:e5734. https:\/\/doi.org\/10.1002\/pds.5734.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1722_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.2338","volume":"77","author":"DD Pennap","year":"2020","unstructured":"Pennap DD, Mosholder AD, Swain RS. Challenges of suicide outcomes ascertainment in administrative claims databases. JAMA Psychiat. 2020;77(1):101. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.2338.","journal-title":"JAMA Psychiat"},{"issue":"9","key":"1722_CR61","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/aje\/kwae034","volume":"193","author":"J Barberio","year":"2024","unstructured":"Barberio J, Naimi AI, Patzer RE, Kim C, Hernandez RK, Brookhart MA, et al. Influence of incomplete death information on cumulative risk estimates in US claims data. Am J Epidemiol. 2024;193(9):1281\u201390. https:\/\/doi.org\/10.1093\/aje\/kwae034.","journal-title":"Am J Epidemiol"},{"key":"1722_CR62","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapsychiatry.2025.1317","volume":"82","author":"A Janik","year":"2025","unstructured":"Janik A, Qiu X, Lane R, Popova V, Drevets WC, Canuso CM, et al. Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2025;82:877\u201387. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1317.","journal-title":"JAMA Psychiat"},{"key":"1722_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.865466","volume":"13","author":"M Roth\u00e4rmel","year":"2022","unstructured":"Roth\u00e4rmel M, Benosman C, El-Hage W, Berjamin C, Ribayrol D, Guillin O, et al. Efficacy and safety of intranasal esketamine in patients with treatment-resistant depression and comorbid chronic post-traumatic stress disorder: open-label single-arm pilot study. Front Psychiatry. 2022;13:865466. https:\/\/doi.org\/10.3389\/fpsyt.2022.865466.","journal-title":"Front Psychiatry"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01722-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:11:32Z","timestamp":1788351092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01722-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":63,"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01722-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G. Caleb Alexander is past Chair of the FDA\u2019s Peripheral and Central Nervous System Advisory Committee and a co-founding Principal and equity holder in Stage Analytics. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. G. Caleb Alexander is an Editorial Board member of\n                      Drug Safety\n                      . G. Caleb Alexander was not involved in the selection of peer reviewers for the manuscript or in any subsequent editorial decisions. You Wang, Alexandra S. Storaci, and Jason B. Gibbons declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and determined exempt by the Johns Hopkins University Institutional Review Board because it used deidentified administrative claims data without direct patient contact. This study was performed in accordance with the Declaration of Helsinki (1964) and its subsequent amendments. Informed consent was not required.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Informed consent was not required under the Johns Hopkins University Institutional Review Board\u2019s exempt determination.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The administrative claims data used in this study are proprietary and were accessed under a data use agreement with Kythera Labs. These data are not publicly available and are subject to restrictions on availability. Access requests should be directed to Kythera Labs (\n                      \n                      ).","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The custom Databricks SQL, SAS, Stata, and Python code used for this study is available from the corresponding author on reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YW: Data curation; formal analysis; methodology; writing\u00a0\u2013 review and editing. ASS: Conceptualization, writing, review, and editing. GCA: Conceptualization, supervision, writing, review, and editing. JBG: Conceptualization; data curation; formal analysis; methodology; project administration; supervision; writing\u00a0\u2013 original draft; writing\u00a0\u2013 review and editing. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}